Clinical data | |
---|---|
Trade names | Methergine |
Other names | Methylergonovine; methylergobasin; Methylergobasine; Methylergobrevin; d-Lysergic acid 1-butanolamide; N-[(2S)-1-Hydroxybutan-2-yl]-6-methyl-9,10-didehydroergoline-8β-carboxamide |
AHFS/Drugs.com | International Drug Names |
MedlinePlus | a601077 |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Liver |
Elimination half-life | 30–120 minutes |
Excretion | Mostly bile |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.003.661 |
Chemical and physical data | |
Formula | C20H25N3O2 |
Molar mass | 339.439 g·mol−1 |
3D model (JSmol) | |
Melting point | 172 °C (342 °F) |
Solubility in water | Insoluble mg/mL (20 °C) |
| |
| |
(what is this?) (verify) |
Methylergometrine, also known as methylergonovine and sold under the brand name Methergine, is a medication of the ergoline and lysergamide groups which is used as an oxytocic in obstetrics and in the treatment of migraine. It reportedly produces psychedelic effects similar to those of lysergic acid diethylamide (LSD) at high doses.[citation needed]
It is on the World Health Organization's List of Essential Medicines.[1]